Doctors still fear risks from Tysabri MS drug

10/23/2006 | San Diego Union-Tribune

Physicians have remaining safety concerns about the multiple sclerosis drug Tysabri, which returned to the market in July, and the risk of a rare, fatal brain disease, according to findings from a Reuters survey. Partly because of that fear, the Biogen Idec and Elan Corp. drug is falling short of analyst projections of more than $100 million in sales.

View Full Article in:

San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ